GlassScriptPhysician profile
Srikanth Koneru
NPI 1003217522
$11,272.86
in general payments reported to CMS, 2019-2025
28 companies · $1,449 in 2025
The $1,449 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,104 · 2020: $361 · 2021: $1,231 · 2022: $2,498 · 2023: $1,994 · 2024: $635 · 2025: $1,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Travel and Lodging: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.32 |
| Travel and Lodging | $514.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,677.32 | 2021-2025 | Corevalve Evolut R, Apollotm |
| Abbott Laboratories | $2,181.86 | 2019-2025 | Diamondback Coronary, Mitraclip, Navitor |
| Edwards Lifesciences Corporation | $2,133.91 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Medtronic Vascular, INC. | $1,133.11 | 2019-2020 | |
| Abiomed | $705.52 | 2020-2022 | |
| Boston Scientific Corporation | $666.71 | 2019-2025 | General - Balloon Catheters, General - Angiography, Watchman Access System |
| Heartflow, INC. | $384.85 | 2019-2024 | Ffrct |
| Irhythm Technologies, INC. | $153.47 | 2024 | Zio Xt Patch, Zio Monitor |
| Cardiva Medical, INC. | $150.74 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 5f Vcs |
| Cardiovascular Systems INC. | $149.47 | 2020-2022 | |
| Amgen INC. | $142.41 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $114.23 | 2021-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $113.43 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $107.28 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.72 | 2023-2025 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.15 | 2024-2025 | Jardiance |
| Ancora Heart, INC. | $49.00 | 2023 | Accucinch |
| Ge Healthcare | $43.43 | 2022 | |
| Impulse Dynamics (USA) INC. | $39.32 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $30.48 | 2023-2025 | Gore Cardioform Asd Occluder, Gore Cardioform Septal Occluder |
| Pfizer INC. | $28.01 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $22.03 | 2024 | Opsumit |
| Nuwellis, INC. | $20.22 | 2025 | Aquadex Smartflow Console |
| Novo Nordisk INC | $19.63 | 2024 | Wegovy |
| Sanofi-Aventis U.S. LLC | $18.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.26 | 2023 | Xarelto |
| Lantheus Medical Imaging, INC. | $14.23 | 2019 | |
| Merck Sharp & Dohme LLC | $13.30 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srikanth Koneru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.